EXTON, Pa.--(BUSINESS WIRE)--
Fibrocell Science, Inc. (FCSC) today announced that LAVIV® (azficel-T) was recognized as the Silver Winner in aesthetics of the science/medical category at the 2013 Edison Awards Ceremony and Gala in Chicago. LAVIV is the first and only autologous cellular product approved by the FDA to improve the appearance of moderate to severe nasolabial folds (smile lines) in adults. The distinguished Edison Awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring creative minds to remain in the forefront of innovation, creativity and ingenuity in the global economy.
“We are honored that the Edison Awards have presented LAVIV with this prestigious accolade for innovation,” said David Pernock, CEO and Chairman of the Board, Fibrocell Science, Inc. “This award highlights the innovative technology behind LAVIV, which isolates, purifies and multiplies a patient’s own collagen-producing fibroblast cells. We look forward to advancing our autologous fibroblast technology to new indications that address areas with high value, unmet medical needs, such as restrictive burn scars, vocal cord scars, and recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic collagen deficiency.”
Hundreds of nominees for the Edison Awards were judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge Edison Award Finalists’ success in meeting the award criteria of Concept, Value, Delivery and Impact. A total of 130 Edison Awards across 15 different categories were presented on April 25, 2013.
About Edison Awards
The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering future innovators. While the Awards honor invention, recognize achievement and celebrate success, Edison Universe is focused on fostering innovation. The 2013 Edison Awards are sponsored by Nielsen, Discovery Communications, Science Channel, and USA Today. For more information about the Edison Awards, Edison Universe and a list of past winners, visit www.edisonawards.com.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
About LAVIV® (azficel-T)
LAVIV is an autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. The safety and efficacy of LAVIV for areas other than the nasolabial folds have not been established. The efficacy of LAVIV beyond six months has not been established.
Important Safety Information about LAVIV® (azficel-T)
LAVIV (azficel-T) is an autologous cellular product for intradermal injection only. LAVIV is contraindicated for allogeneic use, in patients with allergy to gentamicin, amphotericin, dimethyl sulfoxide (DMSO) or material of bovine origin and in patients with active infection in the facial area. The following reactions have been reported following treatment with LAVIV: hypersensitivity reactions, bleeding and bruising at the treatment site, vasculitis, herpes labialis, basal cell cancer; keloid and hypertrophic scarring may occur following post-auricular skin biopsies or LAVIV injections. Additional warnings and precautions to be considered include the use of LAVIV in patients with genetic disorders or formation of normal collagen matrices and in immunosuppressed patients, or those patients undergoing chemotherapy for malignancies or receive immunomodulatory therapies for autoimmune diseases.
The most common adverse reactions, occurring in ≥1% of patients who receive LAVIV, were injection-site redness, bruising, swelling, pain, hemorrhage, edema, nodules, papules, irritation, dermatitis and pruritus.
For more information about LAVIV, please see the accompanying full Prescribing Information or visit www.mylaviv.com.
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.
- Utility Industry
- Thomas Alva Edison
- Science Channel